Drugs / CellgramDC-WT1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06172634 | Mar → Dec 2024 | malignant pancreatic neoplasm | Soonchunhyang University Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cellgram-DC-WT1 | “autologous bone marrow-derived dendritic cells (Cellgram-DC-WT1) made by isolating CD141+ cells from the bone marrow are administered intravenously” NCT06172634 ↗1“Autologous Bone Marrow-derived DCs(CellgramDC-WT1)” NCT06172634 ↗ |
| Modality | Cell therapy | “immune cell therapy using autologous bone marrow-derived dendritic cells” NCT06172634 ↗ |
| Route | Intravenous | “are administered intravenously” NCT06172634 ↗ |